Universitat de Barcelona

Dianes farmacològiques en inflamació i malalties metabòliques

General information

Recogised research group by the Generalitat de Catalunya

Activation of PPARdelta has been proposed as a therapeutic target to prevent metabolic diseases with an inflammatory basis, such as insulin resistance and type 2 diabetes mellitus. However, the putative molecular mechanisms by which PPARdelta activation might be used to prevent or treat these pathologies remain to be established. We thus aim to examine the effects of PPARdelta activators on hyperinsulinemia and inflammation caused by enhanced plasma free fatty acids, cytokines or advanced glycation endproducts in cellular and animal models of insulin resistance. In addition, we are interested in the link between hyperinsulinemia, inflammation and Alzhimer's disease and the potential role of PPARdelta.

UNESCO codes:

Key words:

Thematic area: 5000 - Ciències Mèdiques i de la Salut

Research lines

  • Inflammation and insulin resistance
  • Hyperinsulinemia, inflammation and Alzheimer's disease

Group coordinator

Group members